Francis Chen Joins InSite Vision Board of Directors

InSite Vision (AMEX:ISV) announced today that Francis W. Chen, Ph.D., has been appointed to the company’s Board of Directors, increasing the number of Directors to six. "Francis will be a key asset as we transition InSite Vision to a multiple-product company. His vast knowledge and financial expertise in the healthcare industry will be invaluable as we continue to grow and further expand our offerings,” said S. Kumar Chandrasekaran, Ph.D., Chairman and CEO. Francis Chen, Ph.D., brings more than 30 years of financing and healthcare management expertise to InSite. Francis is a private investor and venture partner at WI Harper Group. He is on the board of a number of portfolio companies, including Interactive Digital Publishing Group, Dermacia, Trace Life Sciences, SB2, Inc., and LogicEase Solutions. Previously, he held senior positions in the healthcare industry at BD (Becton, Dickinson and Company), Baxter Healthcare Corporation, and Hygeia Sciences/Tambrands. Dr. Chen holds a Ph.D. in immunology from Harvard University and an M.S. and a B.S. in chemistry from Tufts University. About InSite Vision InSite Vision develops novel, topical anti-infective products, including AzaSite (azithromycin ophthalmic solution) 1% which was recently launched in the United States by Inspire Pharmaceuticals for the topical treatment of bacterial conjunctivitis (pink eye). Based on its proprietary azithromycin-DuraSite technology platform, InSite is expanding its portfolio of anti-infective ophthalmic products to include AzaSite Plus™ and AzaSite Xtra™, whose product features have the potential to provide significant advantages currently not available with conventional treatment options. In addition, InSite is evaluating the use of its azithromycin-DuraSite platform to develop topical anti-infective products outside of the market category of ophthalmology, beginning with AzaSite Otic™ for ear infections. Forward-Looking Statements This news release contains certain statements of a forward-looking nature relating to future events, such as InSite’s corporate goals, Dr. Chen’s role with, and value to, the company, and the proposed indications and clinical status of the company’s other product candidates. Such statements entail a number of risks and uncertainties, including, but not limited to: InSite Vision’s ability to obtain additional funding to continue its operations; its reliance on third parties, including Inspire, for the commercialization of AzaSite and its other products; the ability of InSite Vision to enter into corporate collaborations for AzaSite outside the U.S. and Canada and with respect to its other product candidates; Inspire’s ability to successfully market AzaSite in the United States and Canada; the clinical results of InSite’s product candidates; InSite Vision’s ability to expand its technology platform to include additional indications; InSite Vision’s ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite, AzaSite Plus, AzaSite Xtra and AzaSite Otic; and its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others; and determinations by the FDA, including those with respect to AzaSite Plus and AzaSite Otic. Reference is made to the discussion of these and other risk factors detailed in InSite Vision’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors” and elsewhere in such reports. Any forward-looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward-looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially, and one should not assume that the information provided in this release is still valid at any later date.